New Skincare Protocol Combats GLP-1 Weight Loss Drug Side Effects on Facial Aging
Flavo-Proxylane topical treatment plus ultrasound reduced skin laxity by 44% in people using weight loss medications.
20 articles
Flavo-Proxylane topical treatment plus ultrasound reduced skin laxity by 44% in people using weight loss medications.
New research reveals pulsed electromagnetic field therapy selectively enhances ATP-linked mitochondrial respiration, pointing to a specific cellular energy mechanism.
Scientists identify MOXD1 as a driver of MASH and show blocking it with a small molecule reverses liver fat accumulation in mice.
A dual-action therapy combining a glucose-responsive hydrogel with stem cell exosomes dramatically speeds diabetic wound closure in mice.
Brief weekly PEMF exposures increased quail embryo weight by ~20%, body length by ~15%, and upregulated key oxidative muscle genes.
Electromagnetic biomaterials offer breakthrough approach to diabetic wound healing by reducing inflammation and promoting tissue regeneration.
HDM1002, an oral GLP-1 receptor agonist, achieved significant weight loss with manageable side effects in overweight Chinese adults.
An erratum to a 2022 Cell Metabolism paper describing a bone marrow lipolytic factor that links mechanical force to bone formation and lymphocyte production.
A landmark JCI review maps the expanding pharmacological arsenal for MASH, from GLP-1 agonists to triple receptor therapies and precision medicine.
Scientists discover how FGF21 fights liver disease through a key protein, opening new treatment paths for metabolic dysfunction.
Advanced incretin-based therapies show potential for major weight loss while protecting heart, kidney, liver, and brain health.
Updated review of anti-obesity medications in MASLD finds GLP-1 agonists reduce steatosis and fibrosis, while newer dual/triple agonists show even greater metabolic promise.
New research reveals how glucose metabolism directly controls fat tissue expansion through a novel epigenetic pathway involving JMJD1A.
New research reveals how the cholesterol medication bempedoic acid directly activates PPARα, boosting fat metabolism beyond its known effects.
A novel endoluminal device implanted in the gut improved insulin sensitivity and weight control beyond what semaglutide achieved in a pig model.
A 16-week RCT finds metformin blocks exercise-induced improvements in artery and capillary function in adults at metabolic syndrome risk.
A comprehensive 2025 review framework matches GLP-1 agonists, tirzepatide, and other AOMs to specific obesity phenotypes, complications, and life stages.
FTO demethylase in AgRP neurons alters Kif1a splicing to boost neuropeptide release, promoting weight gain in mice.
A 2025 mini-review synthesizes RCTs and meta-analyses showing hypertonic dextrose prolotherapy rivals or beats standard OA injections.
Breakthrough modulator therapies are changing how doctors diagnose and treat diabetes in cystic fibrosis patients worldwide.